الفهرس 
Daclatasvir dihydrochlorideOnly 14 pages are availabe for public view
 |  | from | 247 |  |  |
| | | from | 247 | | |
Abstract
A blood-innate viral infection known as chronic
hepatitis C virus (HCV) affects millions of individuals
worldwide and is a leading cause of death. Based on the
variability of the genetic sequence, six HCV genotypes
with several subtypes were identified. Direct-acting
antiviral drug discovery and approval have recently
improved HCV treatment (DAAs). A sustained virological
response (SVR), which is undetectable HCV RNA twelve
weeks (SVR12) or twenty-four weeks (SVR24) after
treatment completion, is the main goal of treating hepatitis
C viral infection. However, certain patients do not respond
to therapy, including those with genotype 3 cirrhosis, those
with resistance-associated substitutions (RAS), or those
with poor treatment adherence linked to social impairments
(homeless, psychiatric illnesses, injection drug use,
alcoholism, etc.). As a result, the creation of fixed dose
combinations (FDC) was started as a method to solve these
issues. The majority of FDCs use the antiviral medications
ledipasvir, valpatasvir, voxilaprevir, daclatasvir, and
elbasvir in addition to sofosbuvir as the primary agent. A
prodrug with direct antiviral activity is sofosbuvir. It works
by impeding RNA polymerase, which thus prevents HCV
from replicating its RNA.